In 135 prefrail hypertensive adults over 65 with chronic kidney disease, followed for one year (105 retained after coarsened exact matching, 52 on dapagliflozin), worse kidney injury tracked with slower walking. Gait speed correlated inversely with albuminuria (r² = 0.48) and positively with eGFR (r² = 0.18), and patients with eGFR below 60 performed significantly worse. In adjusted models, dapagliflozin use carried markedly lower odds of progressing to frailty (OR 0.130; 95% CI 0.045-0.381).
The kidney-to-muscle link is biologically plausible: albuminuria reflects endothelial dysfunction that likely extends to skeletal muscle microvasculature, and CKD drives inflammation, anemia and sarcopenia. SGLT2 inhibitors already have strong trial evidence for slowing CKD progression and cutting heart failure events, so a functional benefit is credible. But an odds ratio of 0.13 is implausibly large for a drug effect, and this is a small, non-randomized study. Residual confounding is the central worry: clinicians may prescribe dapagliflozin to healthier, more engaged patients, and coarsened matching on 105 people cannot fully fix that. Confidence intervals are wide, follow-up is one year, and the frailty endpoint may be sensitive to measurement noise. Treat this as hypothesis-generating rather than practice-changing. It is a useful signal that SGLT2 inhibitors, already indicated for many CKD patients, may protect function as well as organs. A randomized trial with physical performance as the primary endpoint is the logical next step. Older adults with CKD should discuss SGLT2 inhibitors with their physician for established kidney indications, not for frailty prevention alone.